Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
One Percent Rule Checklist For Safer Forex Trading Risk 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
NEW YORK, April 13, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Argos Therapeutics, Inc. (NASDAQ:ARGS) who purchased shares between February 7, 2014 and February 21, 2017. The action, which was filed in the United States District Court for the Middle District of North Carolina, alleges that the Company violated federal securities laws.
The complaint alleges that Argos issued materially false and/or misleading statements, causing the stock to trade at artificially inflated prices; following the release of adverse information, shares of Argos plummeted, damaging investors. In particular, the complaint alleges that Argos issued materially false and/or misleading information regarding the success and potential of its drug candidate AGS-003 (rocapuldencel-T).
On February 22, 2017, despite positive statements made by the Company, Argos announced that the ADAPT study would be discontinued for futility. Following this news, shares of Argos fell approximately 66% to close at $1.48 per share on February 22, 2017.
Shareholders have until May 15, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/argos-therapeutics-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
